

K1232251/3

aap Biomaterials GmbH Lagerstraße 11 – 15 64807 Dieburg Germany	<b>BonOs R</b>		<b>164-0034-01</b>
	<b>5. 510(k) Summary</b>		Date of issue: 11.10.2012
	<b>510(k) Premarket Notification PO-34</b>		page 1 of 3

## 5. 510(k) summary

MAR 15 2013

**Preparation date:** 11.10.2012

**Submitter:** aap Biomaterials GmbH  
Lagerstraße 11-15  
64807 Dieburg  
Germany  
Phone: +49 6071 / 929-0  
Fax: +49 6071 / 929-100

**Contact person:** Volker Stirnal

**Trade name:** BonOs R

**Common name:** PMMA Bone Cement

**Classification:** Polymethylmethacrylate (PMMA) Bone Cement  
21 CFR 888.3027, Class II

**Product Code:** LOD

**Panel:** Orthopedics

### Predicate device to which substantial equivalence is claimed:

<u>Manufacturer</u>	<u>Device Name</u>	<u>510(k) #</u>
Heraeus	Palacos R	(K030902)

aap Biomaterials GmbH Lagerstraße 11 – 15 64807 Dieburg Germany	<b>BonOs R</b>	<b>164-0034-01</b>
	<b>5. 510(k) Summary</b>	Date of issue: 11.10.2012
	<b>510(k) Premarket Notification PO-34</b>	page 2 of 3

### **Device description:**

BonOs R is a fast-setting acrylic resin for use in bone surgery. The bone cement is made of two separate sterile components. When both cement components are mixed together, they become a self hardening, radiopaque bone cement which fixes the Implant and transfers stresses evenly to the bone.

### **Scientific concepts, significant physical and performance characteristics:**

Bone cements in general are self-polymerizing two-component systems comprising a powder and a liquid which polymerize at room temperature immediately after they are mixed together.

The major powder component is polymethyl methacrylate / acrylate. Furthermore a radio-opacifier and benzoyl peroxide as an initiator is included.

The liquid mainly consists of methyl methacrylate. It is furthermore comprised of an activator and a stabilizer to prevent premature polymerization.

When the powder and liquid components are mixed together, the activator, DmpT, contained in the liquid activates the initiator in the powder component. This reaction starts the polymerization of the MMA, which is bonded with the polymer powder during ongoing polymerization. A description of polymerization technology is depicted in section 10- Executive summary, annex 10 – A.

As a result, a viscous paste is obtained which can be introduced into bone using a suitable application system. Heat is generated during setting as a result of the progressive polymerization and exothermic reaction respectively. After curing, the bone cement is able to fix the implant. The setting or curing time is greatly influenced by the temperature of the components and environment, which is common for all acrylic bone cements.

### **Statement of the intended use:**

The BonOs R bone cement is intended for use in arthroplastic procedures of the hip, knee and other joints for the fixation of polymer or metallic prosthetic implants to living bone.

### **Summary of technological characteristics of the new device in comparison to the predicate devices:**

BonOs R bone cement comprises the same materials, mechanical safety and performance as the legally marketed device Palacos R.

aap Biomaterials GmbH Lagerstraße 11 – 15 64807 Dieburg Germany	<b>BonOs R</b>	<b>164-0034-01</b>
	5. 510(k) Summary	Date of issue: 11.10.2012
	510(k) Premarket Notification PO-34	page 3 of 3

Trade Name			BonOs R	Palacos R
Common name			PMMA Bone Cement	PMMA Bone Cement
Responsible manufacturer			aap Biomaterials	Heraeus Kulzer
510(k) Number			-	K030902
Device Classification Name			Cement, Bone	Cement, Bone
Product Code			LOD	LOD
Classification			Class II	Class II
Regulation no.			21 CFR 888.3027	21 CFR 888.3027
Material	Powder	Polymer	Poly(methyl acrylate, methyl methacrylate)	Poly(methyl acrylate, methyl methacrylate)*
		Initiator	Di-benzoyl peroxide	Di-benzoyl peroxide
		Radiopacifier	Zirconium dioxide	Zirconium dioxide
	Liquid	Monomer	Methylmethacrylate (stabilized with hydroquinone)	Methylmethacrylate (stabilized with hydroquinone)*
		Activator	N,N-dimethyl-p-toluidine	N,N-dimethyl-p-toluidine

\* contains Chlorophyll Copper Complex

**BonOs R is substantially equivalent to Palacos R (K030902)** in regard to intended use, materials and operational principles as a bone cement. Equivalence was verified by physical, chemical and mechanical comparative tests to Palacos R.

In summary, BonOs R bone cement is as safe and effective for the declared indications as the predicate device, Palacos R.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-0002

March 15, 2013

aap Biomaterials GmbH  
% Mr. Volker Stirmal  
Director Quality Assurance and Regulatory Affairs  
Lagerstrasse 11-15  
64807 Dieburg  
Germany

Re: K123225  
Trade Name: BonOs R  
Regulation Number: 21 CFR 888.3027  
Regulation Name: Polymethylmethacrylate (PMMA) bone cement  
Regulatory Class: Class II  
Product Code: LOD  
Dated: January 28, 2013  
Received: February 1, 2013

Dear Mr. Stirmal:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Erin D Keith**

Mark N. Melkerson  
Director  
Division of Orthopedic Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

aap Biomaterials GmbH Lagerstraße 11 – 15 64807 Dieburg Germany	<b>BonOs R</b>	<b>164-0033-01</b>
	<b>4. Indications for Use Statement</b>	Date of issue:
	<b>510(k) Premarket Notification PO-34</b>	

#### 4. Indications for Use

510(k) Number: **K123225**

Device Name:        BonOs R

**Indications for Use:**

BonOs R is intended for use in arthroplastic procedures of the hip, knee and other joints for the fixation of polymer or metallic prosthetic implants to living bone.

Prescription Use   X          AND/OR        Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D)        (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Laurence D. Coyne -A

(Division Sign-Off)

Division of Orthopedic Devices

510(k) Number: K123225